ScholarIQanswers from OpenAlex & ORCID
Ruben A. Mesa
ResearcherPublications, citations & collaboration network
Ruben A. Mesa is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ruben A. Mesa have?
ScholarIQindexed works
Ruben A. Mesa has 1,281 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ruben A. Mesa have?
ScholarIQcitation count
Ruben A. Mesa has 46,333 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ruben A. Mesa?
ScholarIQh-index
Ruben A. Mesa has an h-index of 98 in OpenAlex.
What is the i10-index of Ruben A. Mesa?
ScholarIQi10-index
Ruben A. Mesa has an i10-index of 449 in OpenAlex.
What is the ORCID of Ruben A. Mesa?
ScholarIQorcid
The ORCID for Ruben A. Mesa is on the source record.
What is the OpenAlex record for Ruben A. Mesa?
ScholarIQopenalex
The OpenAlex for Ruben A. Mesa is on the source record.
What are the most-cited papers on Ruben A. Mesa?
ScholarIQmost cited works
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera, Sanjay Shete, Chih–Yuan Hsu, Aakash Desai, Gilberto Lopes, Petros Grivas, Corrie Painter, Solange Peters, Michael A Thompson, Ziad Bakouny, Gerald Batist, Tanios Bekaii‐Saab, Mehmet Asım Bilen, Nathaniel Bouganim, Mateo Bover Larroya, Daniel Castellano, Salvatore A. Del Prete, Deborah B. Doroshow, Pamela Egan, Arielle Elkrief, Dimitrios Farmakiotis, Daniel Flora, Matthew D. Galsky, Michael Glover, Elizabeth A. Griffiths, Anthony P. Gulati, Shilpa Gupta, Navid Hafez, Þorvarður R. Hálfdánarson, Jessica E. Hawley, Emily Hsu, Anup Kasi, Ali Raza Khaki, Christopher A. Lemmon, Colleen Lewis, Barbara Logan, Tyler Masters, Rana R. McKay, Ruben A. Mesa, Alicia K. Morgans, Mary F. Mulcahy, Orestis A. Panagiotou, Prakash Peddi, Nathan A. Pennell, Kerry L. Reynolds, L Rosen, Rachel Rosovsky, Mary Salazar, Andrew Schmidt, Sumit Shah, Justin Shaya, John A. Steinharter, Keith Stockerl‐Goldstein, Suki Subbiah, Donald C. Vinh, Firas Wehbe, Lisa B. Weissmann, Julie Wu, Elizabeth Wulff‐Burchfield, Zhuoer Xie, Albert C. Yeh, Peter Paul Yu, Alice Y. Zhou, Leyre Zubiri, Sanjay Mishra, Gary H. Lyman, Brian I. Rini, Jeremy L. Warner, Maheen Z. Abidi, Jared D. Acoba, Neeraj Agarwal, Syed A. Ahmad, Archana Ajmera, Jessica K. Altman, Anne H. Angevine, Nilo Azad, Michael Bär, Aditya Bardia, Jill S. Barnholtz‐Sloan, Briana Barrow, Babar Bashir, Rimma Belenkaya, Stephanie Berg, Eric Bernicker, Christine M. Bestvina, Rohit Bishnoi, Genevieve M. Boland, Mark Bonnen, Gabrielle Bouchard, Daniel W. Bowles, Fiona Busser, Angelo Cabal, Paolo F. Caimi, Theresa M. Carducci, Carla Casulo
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Timothy Devos, Miklós Egyed, Andrzei Hellmann, Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason Gotlib
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, R. S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, E. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, V. Sandor, Hagop M. Kantarjian, For the COMFORT-I investigators
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian, Jason Gotlib, F. Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, V. Sandor, P. Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srđan Verstovšek, on behalf of the COMFORT Investigators